Jan 2025 – Present · 1 yr 2 mos · Remote

Jun 2024 – Present · 1 yr 9 mos · Spain

Nov 2023 – Present · 2 yrs 4 mos · Istanbul, Türkiye

Nov 2022 – Aug 2023 · 9 mos

• Collaborating in a special issue of the well-known journal Genes-MDPI entitled "Genetic Technologies in Cardiovascular Disease; New Tools, Insights, and Opportunities" as the guest editor.

Aug 2022 – Oct 2023 · 1 yr 2 mos · Istanbul, Türkiye · Hybrid

• Findaso is a digital-smart marketplace dedicated to high-level B2B Tech Deals, making collaborations happen in Simple, Agile, and Trusted Ways. Wherever you stand in industry or academia, you can quickly find the perfect solution!

Feb 2022 – Aug 2022 · 6 mos · Istanbul, Türkiye

• As a full-time mother, I did not stop my move within the biotech world and used every single minute of my free time for research. I was involved in a couple of molecular kit designs, business plan preparation for several biotech-based projects, and writing research and review papers.

Feb 2022 – Mar 2022 · 1 mo

Aug 2017 – Feb 2022 · 4 yrs 6 mos

• Head of Mammalian Cell Bank Characterization Projects including the full and partial characterization of CHO, BHK, and SP 2 0 Cell banks producing mAbs and
• recombinant proteins Adalimumab FSH, Pertuzumab Erythropoietin, Aflibercept
• Laronidase Cetuximab Panitimumab Vedolizumab Factor VII, Etanercept
• Rituximab, Trastuzumab Bevacizumab, Tocilizumab Denozumab
• Head of Microbial Cell Bank Characterization Projects including the full and partial characterization of E coli Cell banks producing Somatropin hGH
• Teriparatide Liraglutide Anakinra
• Head of Insect Cell Bank Characterization Projects including the full and partial
• characterization of High five and Sf 9 Cell banks used for recombinant viral
• vaccines
• Head of Virus Bank Characterization Projects including the full and partial characterization of recombinant HPV and Influenza virus banks
• Head of Viral Clearance Study Projects for various products including mAb Adalimumab Recombinant protein (Recombinant vaccines (HPV and
• Influenza vaccines), Human blood derivative product IvIg and Non-human blood
• derivative products (Snake venom antiserum)
• Collaborated with Boomix and Rah Zist Accelerators as technology advisor and
• the referee for various projects including developing GLP-level in vivo based
• infrastructure and reverse engineering of world top glucometers

Jul 2017 – Feb 2022 · 4 yrs 7 mos

• As the QP, I was responsible for
• Ensuring the accuracy, precision, and quality of lab GLP tests and final reports sent
• to clients
• Certifying that each batch of kits (HCD Kits and Mycoplasma Detection kits) meets
• all required provisions when released from the production department
• Company liaison with the Iran Food and Drug organization and responsible for
• advancing the GLP licensing process and successfully attained the Iranian GLP
• Certification

Apr 2017 – Jul 2017 · 3 mos

• Lead the R&D Projects including the development and optimization of new/requested services (e g in vivo testing as part of cell bank characterization) or products (customized HCD kits)
• Performed troubleshooting procedures to solve the emerging in-process issues or to improve the attributes of tests/products
• Accomplished market research and provided feasibility study for new requests and collaboration offers
• Prepared and revised the SOPs, process records, scientific protocols, reports, and documentation of validation and other regulatory documents according to ICH instructions and GLP principles
• Prepared BOM files for services and products

Jan 2016 – Jan 2018 · 2 yrs · Tehran Province, Iran

Feb 2013 – Jan 2017 · 3 yrs 11 mos · Tehran University of Medical Sciences

Feb 2012 – Jan 2017 · 4 yrs 11 mos · Shahid Beheshti University of Medical Sciences